Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cognitive function in breast cancer patients prior to adjuvant treatment.
Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA. Ahles TA, et al. Among authors: kaufman pa. Breast Cancer Res Treat. 2008 Jul;110(1):143-52. doi: 10.1007/s10549-007-9686-5. Epub 2007 Aug 3. Breast Cancer Res Treat. 2008. PMID: 17674194 Free PMC article.
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA; Cancer and Leukemia Group B. Liu MC, et al. Among authors: kaufman pa. Cancer Treat Rev. 2008 May;34(3):223-30. doi: 10.1016/j.ctrv.2007.11.004. Epub 2008 Jan 30. Cancer Treat Rev. 2008. PMID: 18234424 Free PMC article. Clinical Trial.
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE 3rd, Shapiro CL. Mani A, et al. Breast Cancer Res Treat. 2009 Sep;117(1):83-9. doi: 10.1007/s10549-008-0251-7. Epub 2008 Dec 3. Breast Cancer Res Treat. 2009. PMID: 19051009 Free PMC article. Clinical Trial.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Baselga J, et al. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149875 Free PMC article. Clinical Trial.
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL, Kaufman PA. Robertson JF, et al. Among authors: kaufman pa. Lancet Oncol. 2013 Mar;14(3):228-35. doi: 10.1016/S1470-2045(13)70026-3. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414585 Clinical Trial.
139 results